Biogen Inc (BIIB)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+55% over the past year+6
- 52-week positionPressing 52-week highs+30
- QualityRich valuation (P/E 108)-2
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product (the subcutaneous LEQEMBI launch in Japan and related reimbursement/access headlines), with a secondary analyst/industry-report overlay. Continuation likelihood over the next few weeks is moderate-to-low (~30–40%), since launch news tends to be priced quickly and lacks a hard financial surprise. Informational only — not financial advice.
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s DiseaseYahoo · 2026-11-12
- What Moved Alnylam Stock?Yahoo · 2026-11-12
- Every December the Nasdaq-100 Reshuffles. QQQ Holders Feel It Even If They Never TradeYahoo · 2026-11-11
- Gene Therapy - Global Strategic Business Report: Capitalize on 23% CAGR as the Market Hits US$6 Billion by 2030; Benchmark Amgen, Alnylam, BioMarin, Biogen and bluebird bioYahoo · 2026-11-11
- Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion CostsYahoo · 2026-11-11
Any AI summary is an interpretation of public news, not advice or a price target.